Inactive Instrument

Highlights Allena Pharmaceuticals, Inc.

Equities

ALNA

US0181191075

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

ALLENA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	16/22/16	AQ
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Allena Pharmaceuticals, Inc. Provides ALLN-346 Program Update	11/22/11	CI
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2A Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease	19/22/19	CI
ALLENA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	17/22/17	AQ
Allena Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
ALLENA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	01/22/01	AQ
Allena Pharmaceuticals, Inc. Provides A Clinical and Corporate Update	04/22/04	CI
ALLENA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	13/21/13	AQ
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/21/11	CI
Allena Pharmaceuticals Receives FDA Fast-Track Designation for Hyperuricemia Treatment ALLN-346; Shares Jump	03/21/03	MT
Allena Pharmaceuticals, Inc. Receives Fast Track Designation from FDA for Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease	03/21/03	CI
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346	29/21/29	CI
ALLENA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	13/21/13	AQ
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	11/21/11	CI
Allena Pharmaceuticals Provides Update on Clinical Development Programs	12/21/12	CI
Allena Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	09/21/09	CI
Allena Pharmaceuticals, Inc. Announces Initial Data from Phase 1 Trial of ALLN-346	30/20/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Allena Pharmaceuticals, Inc.

Equities

ALNA

US0181191075

Highlights

Filters